Health Care • Medical/Dental Instruments
$1.36 ▼ -0.05
(-3.90%)
MKT CAP: $11.3M • VOL: 110.3K
52W L $1 52W H $22
ROARABLE / RQD
D- • 35/100
PIOTROSKI
4 / 9
FEMY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.3M | $1.6M | $1.1M |
| YoY Revenue Growth % | +40.8% | +52.0% | — |
| Gross Profit | $1.4M | $1.1M | — |
| Gross Margin % | 62.0% | 66.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.6M | -$17.8M | -$14.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$18.6M | -$18.8M | -$14.2M |
| EBITDA (Normalized) | -$17.2M | -$17.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.7M | -$19.4M | -$11.3M |
| Capital Expenditures (CapEx) | $525.0K | $761.7K | — |
| Free Cash Flow (FCF) | -$19.2M | -$20.2M | -$11.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $9.3M | $3.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.9M | $2.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FEMY.